Cargando…

The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

BACKGROUND: Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive primary liver tumor with increasing incidence worldwide, dismal prognosis, and few therapeutic options. Mounting evidence underlines the role of the Hippo pathway in this disease; however, the molecular mechanisms whereby the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cigliano, Antonio, Zhang, Shanshan, Ribback, Silvia, Steinmann, Sara, Sini, Marcella, Ament, Cindy E., Utpatel, Kirsten, Song, Xinhua, Wang, Jingxiao, Pilo, Maria G., Berger, Fabian, Wang, Haichuan, Tao, Junyan, Li, Xiaolei, Pes, Giovanni M., Mancarella, Serena, Giannelli, Gianluigi, Dombrowski, Frank, Evert, Matthias, Calvisi, Diego F., Chen, Xin, Evert, Katja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164528/ https://www.ncbi.nlm.nih.gov/pubmed/35655220 http://dx.doi.org/10.1186/s13046-022-02394-2

Ejemplares similares

Correction: The Hippo pathway efector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease
por: Cigliano, Antonio, et al.
Publicado: (2023)

Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma
por: Cigliano, Antonio, et al.
Publicado: (2019)

Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis
por: Wang, Haichuan, et al.
Publicado: (2020)

Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis
por: Mancarella, Serena, et al.
Publicado: (2020)

CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype
por: Mancarella, Serena, et al.
Publicado: (2022)

Correction: CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype
por: Mancarella, Serena, et al.
Publicado: (2023)

Early Subcellular Hepatocellular Alterations in Mice Post Hydrodynamic Transfection: An Explorative Study
por: Yasser, Mohd, et al.
Publicado: (2023)

Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver
por: Li, Xiaolei, et al.
Publicado: (2015)

The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models
por: Ribback, Silvia, et al.
Publicado: (2016)

SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice
por: Delogu, Salvatore, et al.
Publicado: (2014)

Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development
por: Liu, Pin, et al.
Publicado: (2017)

Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice
por: Cigliano, Antonio, et al.
Publicado: (2017)

Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model
por: Dong, Mingjie, et al.
Publicado: (2018)

Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice
por: Hu, Junjie, et al.
Publicado: (2016)

Oncogene-dependent function of BRG1 in hepatocarcinogenesis
por: Wang, Pan, et al.
Publicado: (2020)

PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men
por: Ribback, Silvia, et al.
Publicado: (2015)

Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans
por: Che, Li, et al.
Publicado: (2020)

Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis
por: Jia, Jiaoyuan, et al.
Publicado: (2020)

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
por: Shang, Runze, et al.
Publicado: (2021)

Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade
por: Jia, Jiaoyuan, et al.
Publicado: (2017)

Fascin1 empowers YAP mechanotransduction and promotes cholangiocarcinoma development
por: Pocaterra, Arianna, et al.
Publicado: (2021)

Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway
por: Xu, Zhong, et al.
Publicado: (2018)

Hippo-YAP/TAZ signaling in angiogenesis
por: Park, Jeong Ae, et al.
Publicado: (2018)

Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition
por: Mancarella, Serena, et al.
Publicado: (2022)

Functional role of SGK3 in PI3K/Pten driven liver tumor development
por: Cao, Hui, et al.
Publicado: (2019)

Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms
por: Dobrokhotov, Oleg, et al.
Publicado: (2018)

Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: Implications for the treatment of human liver cancer
por: Wang, Chunmei, et al.
Publicado: (2013)

eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma
por: Steinmann, Sara M., et al.
Publicado: (2023)

Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma
por: Calvisi, Diego F., et al.
Publicado: (2012)

Hippo-Yap/Taz signalling in zebrafish regeneration
por: Riley, Susanna E., et al.
Publicado: (2022)

Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis
por: Cigliano, Antonio, et al.
Publicado: (2017)

Hippo Pathway-independent Restriction of TAZ and YAP by Angiomotin
por: Chan, Siew Wee, et al.
Publicado: (2011)

Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis
por: Boopathy, Gandhi T. K., et al.
Publicado: (2019)

Control of skeletal morphogenesis by the Hippo-YAP/TAZ pathway
por: Vanyai, Hannah K., et al.
Publicado: (2020)

The Roles of YAP/TAZ and the Hippo Pathway in Healthy and Diseased Skin
por: Rognoni, Emanuel, et al.
Publicado: (2019)

The Roles of Hippo Signaling Transducers Yap and Taz in Chromatin Remodeling
por: Hillmer, Ryan E., et al.
Publicado: (2019)

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma
por: Liu, Xianqiong, et al.
Publicado: (2019)

Hepatocellular glycogenotic foci after combined intraportal pancreatic islet transplantation and knockout of the carbohydrate responsive element binding protein in diabetic mice
por: Ribback, Silvia, et al.
Publicado: (2017)

MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment
por: Wang, Pan, et al.
Publicado: (2019)

The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma
por: Mohamed, Abdalla, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p8cbqinpnfp076absf1gmrthrg